Medindia

X

Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting

Saturday, March 29, 2008 General News J E 4
Advertisement
MOUNTAIN VIEW, Calif., March 28 PharsightCorporation (Nasdaq: PHST), a leading provider of software, strategicconsulting, and regulatory services for optimizing clinical drug development,today announced that Bill Poland, Ph.D., vice president and lead scientist,Strategic Consulting Services, has been invited to present at the AmericanSociety for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting atthe Orlando World Center Marriott Resort in Orlando, Florida. Dr. Poland willpresent on April 4, 2008, joining other leading experts from thepharmaceutical industry and academia in a symposium focused on applications ofpharmacokinetic/pharmacodynamic (PK/PD) and disease modeling in HIV.

The symposium will provide a forum for scientific discussion andcollaborative exchange on model-based approaches to describe and predict drugeffects in the treatment of HIV, and will include specific case examples wheredrug-disease modeling have optimized the clinical development of new anti-HIVdrugs. Dr. Poland's presentation, entitled "Using in Vitro and Literature Datato Predict Effects of New Anti-Retrovirals", will describe how PK/PD-viraldynamics models developed using preclinical data and literature data onexisting HIV treatments can inform dose-response predictions for newanti-retroviral agents.

In addition to Dr. Poland's presentation, Pharsight scientists havecontributed to two separate ASCPT poster presentations that describemodel-based approaches to support development decision-making and clinicaltrial design for drug candidates in oncology and obesity. Further informationcan be found at http://www.ascpt.org.

"Integrating literature information to permit objective comparisons ofdrug effects and time course of disease is a critical knowledge managementstrategy in model-based drug development," said Shawn O'Connor, president,chief executive officer, and chairman of Pharsight. "Model-based approachescontinue to show value for enhancing the understanding of complicated diseasesin quantitative terms, and for improving the confidence of drug developmentdecisions. Pharsight is pleased to present at this prestigious HIV symposiumand to participate at ASCPT, where we look forward to sharing our experiencewith industry colleagues and interacting with fellow practitioners of modelingand simulation."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products andservices that enable pharmaceutical and biotechnology companies to achievesignificant and enduring improvements in the development and use oftherapeutic products. Pharsight's goal is to help customers reduce the time,cost and risk of drug development, as well as optimize the post-approvalmarketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug developmentsuccess: strong decision-making. By adopting the Pharsight approach, customersacquire a new decision-making process with the potential to systematicallyimprove every level and phase of their business and scientific processes.Pharsight Corporation is headquartered in Mountain View, California.Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All otherbrand or product names mentioned in this documentation are trademarks orregistered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Vical Licensee AnGes MG Files NDA in Japan for Col...
S
VaxGen and Raven Terminate Merger Agreement